Eli Lilly’s commitment to personalised medicine is demonstrated with its latest agreement with pharmacogenetics company, Cabernet Pharmaceuticals. Lilly sees the application of a pharmacogenetics approach to some of its drug development programmes as an important strategy in developing competitive drugs that could counteract imminent patent expiries of some of its major drugs.